Top Markets
Coin of the day
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rangering i aksjer #5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Aksjekurs
$36.98
Sist synkronisert: 2026-08-26
Markedsverdi
$2.58B
Endring (1 dag)
-0.67%
Endring (1 år)
55.51%
Land
NL
Handel Pharvaris N.V. (PHVS)

Kategori

P/B-forhold for Pharvaris N.V. (PHVS)
P/B-forhold per 2026 TTM: 0
Ifølge Pharvaris N.V. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Pharvaris N.V. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH